| Robert R Tota, MD | |
|
4675 Main St, Bridgeport, CT 06606-1813 | |
| (203) 683-5100 | |
| (203) 683-5140 |
| Full Name | Robert R Tota |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 4675 Main St, Bridgeport, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558309799 | NPI | - | NPPES |
| 001332098 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 033209 (Connecticut) | Primary |
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720013360 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000785 |
News Archive
Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
The expansion of Medicare included in a Senate compromise hailed as a breakthrough in the discussions of health care overhaul earlier this week is now encountering some friction.
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
Researchers at NorthShore University HealthSystem have launched the first clinical trial to investigate a genetic risk score (GRS) test to predict the risk of breast, prostate and colorectal cancer in the primary care setting.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert R Tota, MD 4675 Main St, Bridgeport, CT 06606-1813 Ph: (203) 683-5100 | Robert R Tota, MD 4675 Main St, Bridgeport, CT 06606-1813 Ph: (203) 683-5100 |
News Archive
Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.
The expansion of Medicare included in a Senate compromise hailed as a breakthrough in the discussions of health care overhaul earlier this week is now encountering some friction.
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy.
Researchers at NorthShore University HealthSystem have launched the first clinical trial to investigate a genetic risk score (GRS) test to predict the risk of breast, prostate and colorectal cancer in the primary care setting.
› Verified 6 days ago
Mitchell Andrew Fogel, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 900 Madison Ave, Suite 209, Bridgeport, CT 06606 Phone: 203-335-0195 Fax: 203-335-7293 | |
Christian Heineken, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3180 Main St, Suite 301, Bridgeport, CT 06606 Phone: 203-373-9100 Fax: 203-365-8492 | |
Pasquale Masone, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 3180 Main St, Suite 301, Bridgeport, CT 06606 Phone: 203-373-9100 Fax: 203-365-8492 | |
Kevin B Panzer, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1381 Reservoir Ave., Bridgeport, CT 06606 Phone: 203-371-5197 | |
Ms. Lucia Plichtova, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 267 Grant Street, Bridgeport, CT 06610 Phone: 203-384-3792 | |
Hilda Daureen Kyotakoze, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4920 Main St Fl 2, Bridgeport, CT 06606 Phone: 203-371-2986 | |
Karen A Hutchinson, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 226 Mill Hill Ave, 3rd Floor, Bridgeport, CT 06610 Phone: 203-384-3873 Fax: 203-384-3829 |